Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clostridium novyi-NT - BioMed Valley Discoveries

Drug Profile

Clostridium novyi-NT - BioMed Valley Discoveries

Alternative Names: BVD-550; BVD-CNV; BVD-CNV/IT; BVD-CNV/IV; C.novyi-NT; Clostridium novyi-NT spores; Clostridium-novyi-non-toxic; CNV-NT

Latest Information Update: 24 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioMed Valley Discoveries; Johns Hopkins University
  • Developer BioMed Valley Discoveries; M. D. Anderson Cancer Center; Merck Sharp & Dohme
  • Class Antineoplastics; Bacteria
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 14 Apr 2023 Clostridium novyi-NT is still in phase I trials for solid tumours in USA
  • 14 Apr 2023 Efficacy and adverse events data from a phase I trial in solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 14 Apr 2023 BioMed Valley Discoveries plans a phase II trial for Solid tumours
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top